Repositive – the Cambridge-based startup that connects researchers with the right preclinical cancer models for their research – today announced the appointment of Slaven Stekovic as Head of Strategic Growth, along with leading commercial experts (Mariana Vaschetto and Francesca Crawford) to its advisory board, to drive the company’s scale-up and global growth ambitions within the pharma and biotech market.
Coulter Partners was very pleased to partner once more with innovative medicine enabling nanotechnology company, Nanoform to secure the appointment of Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that James Keeling has been appointed as Chief Financial Officer (CFO).
We're thrilled to announce the appointment of Dr Ken Powell as Chair to the Board of Directors for Theolytics. Ken brings extensive virology and commercial expertise, including from founding roles at Arrow Therapeutics and Reviral.
Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019. Nigel Davis, the current CEO, will remain with the Company as Chief Business Officer.